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TP53 gene mutations and protein accumulation in prmary vaginal
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Summary Primary carcinomas from 46 patients were screened for TP53 alterations. Immunohistochemistry
demonstrated nuclear TPS3 protein accumulation in 22 (48%) cases using the polyclonal CM1 antiserum,
whereas 15 (33%) cases showed positive nuclear staining with the mononuclear antibody PAb 1801. Constant
denaturant gel electrophoresis (CDGE) was used to screen 27 of the vaginal carcinomas for mutations in the
conserved regions of the TP53 gene (exons 5-8). Six of these tumours (22%) contained mutations: four were
found in exon 5 and two in exon 8. A total of 50% of the primary vaginal carcinomas carried a TP53
alteration. These results indicate that TP53 abnormalities may be involved in the development of these
tumours. However, there was no significant association between TP53 abnormalities and survival.
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The TP53 tumour-suppressor gene, which encodes a 53 kDa
cell cycle regulator nuclear phosphoprotein, is located on the
short arm of chromosome 17. The product of this gene has
been implicated in the control of the cell cycle, DNA repair
and synthesis, cell differentiation and programmed cell death
(Harris and Hollstein, 1993). Some mutant forms of the gene
can act as dominant oncogenes, whereas wild-type TP53 has
characteristics of a recessive tumour-suppressor gene (Lane
and Benchimol, 1990). Although the precise mechanism by
which the TP53 protein participates in these cellular func-
tions is not fully understood, several biochemical features of
TP53 have been elucidated. The TP53 protein is able to
regulate transcription directly (Kern et al., 1991; El-Deiry et
al., 1992) or by interacting with other transcriptional
regulatory factors, such as the TATA- and CAAT-binding
proteins (Seto et al., 1992; Agoff et al., 1993). The TP53
protein has also been shown to act as a specific transcription
factor controlling the expression of growth arrest genes such
as GADD45 (Kastan et al., 1992) and WAF-I (El-Deiry et
al., 1993).
Mutations in the TP53 gene are the most frequent genetic
alteration found in human tumours (Hollstein et al., 1994;
Levine et al., 1994). The ability to transactivate gene expres-
sion from a specific promoter sequence is lost in most TP53
mutants associated with cell transformation and oncogenesis
(Kern et al., 1991). The mutations are usually missense and
are frequently accompanied by loss of the remaining normal
allele. Furthermore, mutated proteins are able to bind and
activate wild-type TP53 protein by forming oligomeric
complexes (Nigro et al., 1989). Point mutations in the TP53
gene often result in increased stability of the mutant protein
(Finlay et al., 1988), which can be detected by immunohis-
tochemistry, whereas the wild-type TP53 protein is undetec-
table because of its short half-life (Gronstajaski et al., 1984).
However, under certain circumstances accumulation of wild-
type TP53 protein may occur, probably because of complex
formation with other cellular proteins such as MDM2
(Momand et al., 1992), or virus proteins like the large T
antigen of SV40 (Lane and Crawford, 1979).
There is increasing evidence that tumour-suppressor genes
are involved in the development and/or progression of
gynaecological malignancies. Mutations or loss of hetero-
zygosity at the TP53 locus have been reported in ovarian
(Bosari et al., 1993; Kohler et al., 1993a), endometrial
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(Kohler et al., 1993b; Yu et al., 1993) and cervical cancers
(Helland et al., 1993; Holm et al., 1993). To our knowledge
abnormalities of the TP53 tumour-suppressor gene have not
been studied in vaginal carcinomas. Among gynaecological
cancers, carcinoma of the vagina is relatively rare. It
accounts for only 1-2% of all gynaecological cancers (Pride
et al., 1979).
The aims of the present study were to determine the fre-
quency ofTP53 protein accumulation and TP53 mutations in
a series of primary vaginal carcinomas. Furthermore, we
wanted to correlate TP53 alterations with histopathological
and clinical parameters and to evaluate whether these altera-
tions provide prognostic information in vaginal carcinomas.
Matedals and methods
Twnour samples
Forty-six cases of vaginal carcinomas, diagnosed in the
period 1973-94, were collected from the files of the
Norwegian Radium Hospital. The mean age at diagnosis was
66 years (range 31-87 years). The median observation time
of the patients still living was 43 months (range 1-214
months). Histopathological and clinical diagnoses are shown
in Table I. Immediately after surgery the tissue was fixed in
10% formalin, embedded in paraffin and processed for light
microscopy. Three of the tumour samples were also frozen
and stored in liquid nitrogen for DNA analyses. Haematoxy-
lin-eosin-stained sections were used to evaluate the approx-
Tae I Histopathological/clinical diagnoses and TP53 alterations
No. (%) ofpatients
Variable Total With TP53 alteratwn
FIGO stage
I 13 5 (38)
II 19 9 (47)
III 9 5 (56)
IV 5 4(80)
Differentiation grade
High 5 2 (40)
Moderate 35 16 (46)
Poor 6 5 (83)
Histologia type
Squamous cedlcarnoma 41 21 (51)
Adenocarcinoma 3 1 (33)
Other 2 1 (50)1F53awA.m in *W.cuIn
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imate percentage of tumour tissue. Samples with kss than
10% tumour tissue were not used for DNA analysis.
DNA analysis
DNA was isolated from 27 tumour samples using the method
of Mies et al. (1991). Five to ten 10jim tissue sections of the
paraffin-embedded samples were collcted in a 2ml Eppen-
dorf tube, deparAffinised with Hioclear (Histolab, Sweden)
and rinsed in 100% alcohol. The deparaffiised sections and
crushed frozen tissue were did with proteinas K (Sigma,
USA) at a final concentration of 0.5 mgml-' in 0.05 M
Tris-HCI buffer containing 0.15M sodium chbride, 5mM
EDTA and 1% SDS (pH9.0). Digestion was performed at
55 C for 3-7 days. Protein was removed by phenol-chloro-
form extraction and DNA isolated by ethanol prcipitation.
Samples were handled carefully to inimi mechanical
stress, and wide-bore pipettes were used to transfer aqueous
solutions containing high molecular weight DNA.
Polymerase chain reaction (PCR) was performed using
oligonucleotide primers as previously described (Borresen et
al., 1991). The primer sets used amplfied across the four
conserved regions where more than 80% of TP53 mutations
have been identified: codons 128-153 (exon 5, fragment A);
codons 155-185 (exon 5, fragment B); codons 237-253
(exon 7, fragment C); and codons 265-301 (exon 8, fragment
D). PCR was performed in 50jl reaction vohm using
300-600 ng of templt DNA in 10mm Tris-HCI (pH 8.6),
50mM potasum chloride, 15mM magnesum chloride,
0.2 mm of each dNTP, 25 or 50pmol of each prm
(25 pmol of purified primer and 50pmol of unpurified
prime) and 1.25 units of Taq polymerase (AmpliTaq, Cetus,
USA). The reaction mixture was incubated in a Perkin-
Elmr/Cetus thermocycler for 40 cycles at 94C (90s), 55C
(90s) and 72-C (120s). The reaction was initiated with one
7-mm incubation at 94-C and ended with 10min incubation
at 72C, 4 min incubation at 94-C and 60m incubation at
65YC. PCR products were analysed for purity on a 7.5%
polyacrylamide gel. Samples giving a low yield of PCR pro-
duct were usually reamplified using the PCR product as a
template.
The four amplified products from each tumour were
screened for TP53 mutations using constant denaturant gel
eectrophoresis (CDGE) (Borresen et al., 1991; Hovig et al.,
1991). Denaturing gels contained 12% acrylamide with vary-
ig denaturant concentrations consisting of urea and for-
mamide (fragment A, 45.5% and 55%; frgment B, 55%;
fragment C, 49.5%; and fragment D, 49.5%; 100%
denaturant corresponds to 7 M urea and 40% formamide).
Gels were run submerged in TAE buffer (40mM Tris-
acetate, I mM EDTA, pH 8.0) at 56-C at 80V for 3-4h.
After electrophoresis, gels were stained for a few minutes in
ethidium bromide (2mg1-' TAE) and photogaphed ng a
UV nsilluminator. Samps showing aberrant migration in
CDGE were reamplified, and to confirm a true mutant
denaturing gradiet edtrophoresis (DGGE) (Borfesen et al.,
1991) was performed. The gadient gels were cast with a
gravitational gradient mixer. The PCR product was loaded
into a long well on top of the gel and run with the detro-
phoresis direction pependicular to the denaturant gradienLt
The gels, which had the same chemicals and ekctrophoresis
conditions as the constant denaturing gels, were run for 2 h
with the gradient spanning from 10% to 70% denaturant.
Gradient gels were stained and photographed usng both
ethidium bromide, as described above, and SYBR green I
(Molkuar Probes, Eugene, OR, USA) diluted 1:10000.
Samples that carried a mutation were amplified with one
biotinylated primer. The PCR products were sequenced with
dideoxy sequencing reactions using Dynabeads M280-Strp-
tavidin (DynaL Norway) as solid support (Hultman et at.,
1989). Oligonucleotides flaning each of exons 5, 7 and 8
were used to prime the reactions, which were performed by
first heating the primer-template mix (70 C). Then the sam-
ples were labeLlld for 10min with [3SJdCTP, and the ter-
mination reactions were run with Sequenase 2.0 17 DNA
polymerase (US Biochemicals) at 3TC for 10min. The reac-
tion products were electrophoresed on a 4.3% polyac-
rylamide gel, which was dried and autoradiographed with
Kodak Hyperfilm-MP beta-max overnight.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue specimens from 46
cases were used for munhistochemical staining with the
avidin-biotin-peroxidase complex (ABC) method (Hsu et
al., 1981). Deparaffinised sections were treated with 0.3%
hydrogen peroxide in methanol for 30min to block
endogenous peroxidase. The sections were incubated for
20min with normal serum from the species in which the
secondary antibody was made. This was done to eliminate
non-specific staining. Excess normal serum was blotted from
the slides before incubation with a polyclonal TP53
antiserm (NCL-CM1, Novocastra Laboratory, UK) diluted
1:300 and a monoclonal TP53 antibody (PAb 1801,
Oncogene Science, NY, USA) diluted 1:100 (1 Mg ofIgG, per
ml) for 18-22 h at 4C. Both antibodies detete mutant and
wild-type TP53. The sections were then incubated with a
1:200 dilution of biotin-labeled secondary antibody for
30min and ABC (10 igml-' avidin and 2.4jgml ' biotin-
labelled peroxidase) (Vector, Burlingame, CA, USA) for
60min. The tissue was stained for 5min with 0.05% 3,3'-
diaminobenzidine tetrahydrochloride (DAB) freshly prepred
in 0.05 M Tris buffer at pH 7.6 containing 0.01% hydrogen
peroxide. Sections were then countetained with haematoxy-
fin, dehydrated and mounted in Diatex. All the dilutions of
normal sera, antisera, biotin-labeiled secondary antibodies
and ABC were done with phosphate-buffered saline (PBS),
pH 7.4, containing 5% bovine serum a in
All series incuded positive controls Negative controls
included replcement of polyclonal prmary antisrum with
rabbit serun diluted 1:300, whereas negative controls for the
monoclonal antibody were performed usng mouse myeloma
protein of the same subclass and concentration as the
monoclonal antibody. All controls gave satisfactory results.
Statistical analysis
Differences in proportion were evaluated by the chi-square
test Cancer-related survival was lalcted from start of
treatment to death of diseas, or 31 May 1994, usng the
method of Kaplan and Meier (1958). Diffaences in surival
were evaluated usng the log-rani test (Tarone and Ware,
1977). A P-ievel less than 0.05 was conidere atistically
signifiCant.
Rests
TP53 mutation analysis
Of the 46 samples that were subjected to immunotaining,
sUffiCient material for CDGE and DGGE analyses were
available for 27 samples. Six (22%) of these tumours con-
tained mutations: four were identified in exon 5 and two in
exon 8 (Table II, Figure la and b). Of the mutations found
in exon 5, two reside in fr nt A (codons 128-153) and
two in f nt B (codons 155-185). Direct sequencig
required more templat DNA and PCR product than the
CDGE and DGGE analysis. Sequencing results were thus
obtained for only one tumour sample that was mutated
according to CDGE and DGGE. This DNA was extracted
from one of the fresh-frozen tumours. Sequening revealeA
the mutation to be a G:C+C:G taversion in codon 280
(Figure lc). The AGA+ACA change corresponds to a
missnse mutation, arn to threonine.
TP53protein mnostainng
Immunohistochemistry demonstrated TP53 protein accumu-
lation in 22 of 46 (48%) primary vaginal carcinomas usingTable I TP53 protein accumulation and TP53 gene mutations
Immunohistochemistry
Patient no. PAb 1801 CM] Mutation in exonr
1+ + 8
2 +++ +++ 8
3 - ++ 5
4 - +++ 5
5 + ++ 5
6 - - 5
7 + + _
8 +++ +-++
9 _ + -
10 +++ ++
11 + ++ _
12 ++ ++
13 + +
14 + ++ ND
15 - + ND
16 + ++ ND
17 ++ ++ ND
18 + ++ ND
19 - ++ ND
20 - + + ND
21 + + ND
22 - ++ ND
23 + +++ ND
24 to 37 - - -
38 to 46 - - ND
-, Noimmunoreactivecells ormutationnotdetected; +, <5% cells
with immunoreactive nucleus; + +, 5-50% cells with immunoreactive
nucleus; + + +, >50% cels with immunoreactive nucleus. ND, not
done (suitable material not available). 'Mutation detected by abberant
migrating bands in CDGE and DGGE.
the polyclonal CM1 antiserum (Table II, Figure 2), whereas
15 of 46 (33%) cases showed positive staining with the
monoclonal antibody PAb 1801 (Table II). The cases that
were positive with the monoclonal antibody were all
imunoreactive with the polyclonal antiserum. The TP53
protein-immunopositive cases exhibited granular or diffuise
nuclear staining, and the proportion of immunoreactive cells
varied between tumours (Table II). No positive staining was
observed in normal tissues adjacent to tumours.
Correlation between mutation and immunohistochemical data
The concordance between mutation and immunohisto-
chemical data from samples that were subjected to both types
of analyses was 70% when both positive and negative results
were taken into consideration. In 14 tumours neither TP53
mutation nor TP53 protein accumulation was observed,
whereas five cases exhibited both TP53 protein accumulation
and mutations. One of the mutated tumours did not exhibit
an elevated level of TP53 protein. In seven of the tumours
that were TP53 protein positive a mutation was not
identified. Of these seven cases, three accumulated TP53
protein in less than 5% of the tumour cells. In total, 50% of
primary vaginal carcinomas carried TP53 alterations.
TP53 alterations and clinicalparameters
The frequency of TP53 mutations and protein overexpression
seemed to increase with increasing FIGO stage. However, the
difference was not statistically significant (P = 0.41). There
were no differences between the TP53 mutant/immunohisto-
chemical positive and negative cases regarding histological
type or grade of differentiation (Table I). The 5 year cancer-
related survival in the two groups was 47% and 42% respec-
tively (P = 0.95).
Among gynaecological cancers, carcinoma of the vagina is
relatively rare, accounting for 1-2% of all gynaecological
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Fugwe I Mutation analysis of the TP53 gene, case no. 2. (a)
Constant denaturant gel electrophoresis (CDGE) of PCR-
amplified exon 8, codon 280 mutant (AGA+ACA) (lane 3) and
wild-type tumours (lanes 1-2 and 4-5). The 12.5% polyac-
rylamide gel contained 45% denaturant (100% denaturant corres-
ponds to 7 M urea and 40% formamide) and was run for 2 h at
56-C at 80 V. htdx, heteroduplex; mut, mutant; wt, wild type. (b)
Denaturing gradient gel electrophoresis (DGGE) of PCR-
ampified exon 8. The 12.5% polyacrylamide gels were run in a
gradient from 10% to 70% denaturant. The PCR product was
loaded into a long well on top of the gel and run with the
electrophoresis direction perpendicular to the denaturant gradient
for 2 h at 56-C at 80 V. (c) Sequencing analysis of PCR-amplified
exon 8. An AGA+ACA substitution is seen in codon 280.
cancers (Pride et al., 1979; Podczaski and Herbst, 1986).
Owing to the low frequency of their occurrence, studies on
these tumours are few. Previously, human papillomavirus
(HPV) infection (Ikenberg et al., 1990) has been demon-
strated in vaginal carcinomas. To our knowledge, abnor-
malities of the TP53 tumour-suppressor gene have not been
70: :
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Fe 2 Case no. 2. The majority of tumour cells show strong
TP53 protein nuclear with the polyclonal CMI
antiserum.
studied in these malignncies. The present study demon-
strated TP53 protein accmulation in 22 of 46 (48%) cases
and mutations in six of 27 (22%) cases. A total of 50% of
the primary vaginal caranomas showed TP53 gene mutation,
and/or protein accumulation. The rates of TP53 alterations
in these vaginal carcinomas are similr to what has been
observed in other gynaecological cancers. TP53 alterations
are found in 55% of ovarian cancers (Bosari et al., 1993;
Marks et al., 1993), 59% of endometrial cacrs (Bur et al.,
1992) and 62% of cervical cancers (Hohm et al., 1993). Our
results indicate that TP53 abnormalities also may be involved
in the development of vaginal carcinomas.
To our knowledge, no study has investigated the relation-
ship between HPV DNA and TP53 alterations in vaginal
carcinomas. Previously, an inverse relationship between the
presence of HPV DNA and TP53 gene mutation in cell lines
(Sheffner et al., 1991) and in primary cervical carcinomas has
been demonstrated (Crook et al., 1992), whereas others have
identified TP53 alteration and HPV DNA in the same cases
of cervical carcinomas (Busby-Earle et al., 1992; Helland et
al., 1993). In vaginal carcinomas we did not find an inverse
relationship between HPV DNA and TP53 alterations. In 11
of 14 cases with TP53 alteration, HPV 16 was also detected
(unpublished findings).
In the present study there was a 70% correlation between
mutation and immunohistochemical data. This is in contrast
to earlier studies in which a highly signnt association
between the presence of TP53 mutations and TP53 protein
accumulation was observed (Andersen et al., 1993; Marchetti
et al., 1993). In previous studies, an increasing number of
tumours with TP53 protein accumulation without altered
DNA have been found (Helland et al., 1993; Lae, 1994).
Seven of the tumours that were TP53 protein positive by
immunohistochemistry were not found to be mutated. Of
these seven cases, three showed a very small fraction of TP53
protein-positive cells. Therefore, the number of mutated cells
may have been too low to be de by CDGE, although as
few as 1-5% of mutated cells could be detected by this
method (Andersen and Borresen, 1995). Furthermore, some
of the tumours could have mutations outside the four
screened regions of the gene, or have alterations in the TP53
regulator sequences. Another explanation is that the tumours
may have accumulated wild-type TP53 protein. It has
recently been shown that cell stress resulting from external
DNA-damaging agents can lead to accumulation ofwild-type
TP53 protein in normal skcin (Hall et al., 1993; Fritsche et al.,
1993). Nevertheess, this phenomenon is unlikely, as we never
found TP53 protein in normal tissues surrounding the
tumours. However, internal DNA damage could be limited
to the tumour cells. Alternatively, wild-type TP53 protein
may have formed complexes with other proteins such as
MDM2, resulting in a higher level of inactive TP53 protein
(Oliner et al., 1992). In one of the mutated samples we failed
to find a positive immunoreaction. A mutation implying a
shift in reading frame or a stop codon could lead to a change
in a large proportion of the quatemary structure of the
protein which would result in the absnce of TP53 immuno-
staining (Andersen and Borresen, 1995). Lack of immuno-
staining could also be explained by the presence of a sense
mutation that does not stabilise the protein sufficiently.
CDGE and DGGE analysis identified TP53 gene muta-
tions in six of27 (22%) vaginal carcinomas. We were able to
determine the exact nature ofthe mutation by direct sequenc-
ing only in the DNA extracted from the fresh-frozen tissue.
This method required more template DNA and PCR product
than CDGE and DGGE analysis. The sequencing prims
were different from the CDGE and DGGE primers. It is
therefore possible that formalin fixation had degraded or
modified the DNA in a way that disturbed anling of the
sequencng primers or, alternatively, the chain elongation.
The amount of tissue from each sample was scarce, and thus
sequencing would most likely be more successful when done
on a largr amount of tissue. Previously, the CDGE/DGGE
technique has proved to be highly rehable, with a detection
rate of 100% of mutants in exon 5, 7 and 8 under optimal
conditions (Condie, 1993). All samples with aberrant migrat-
ing bands in DGGE displayed heteroduplex formation. The
heteroduplexes that are easily recognised in melting gels
enable detection of mutations when present in 1-5% of the
cell population (Andersen and Borresen, 1995).
Numerous antibodies detecting TP53 protein are available.
We observed positive immunoreactivity more often with the
polydonal antiserum CM1 than with the monoclonal
antibody PAb 1801. This discrepancy may be due to
aceumulation of TP53 protein with a configuration detted
by the polyclonal but not the monoclonal antibody. In addi-
tion, the failure of PAb 1801 to detect TP53 protein in some
specmens immunoreactive with CM1 could be because the
epitope recognised by PAb 1801 antibody is not stable in
formalin-fixed tissu (Purdie et al., 1991).
No correlation was ssen between TP53 alteration and sur-
vival of patients with vaginal carcinomas. This is in agree-
ment with other studies that fail to find prognostic
significae in cancers of the ovary (Marks et al., 1992;
Kohler et al., 1993a) and cervix (Helland et al., 1993; Oka et
a!., 1993). In contrast, other groups ofinvestigators observed
a relationship between behaviour and TP53 altera-
tion in cancers of the ovary (Bosari et al., 1993) and
endometrium (Bur et al., 1992). Our study inluded a limited
number of cases, and therefore further studies of a largr
amount ofmaterial are needed to better define the prognostic
significae of TP53 alterations in patients with vaginal
cancer.
In conclusion, TP53 alterations were dedtet in 50% of
primary vaginal carcinomas by use of genetic and immuno-
histochemical techniques. These results indicate that TP53
abnormalities may be involved in the development of these
tumours. However, there was no signnt correlation
between TP53 alteration and survival.
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